ResearcherAir Force Medical UniversityActive in the last 2 years

Bang‐Le Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9008-5391; OpenAlex author ID A5013564891. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2024: 2 papers

Papers 2

Anti-PD-L1 checkpoint inhibitor combined with nanocarrier-mediated cisplatin codelivery system for effective treatment of pancreatic cancer. Last author DOI 10.1016/j.molimm.2024.08.006 ↗
Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic treatment of pancreatic ductal adenocarc… Last author DOI 10.1186/s12951-024-02646-7 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zhou-Yan Jia · 2 shared papers, 2024 · strength 0.49
- Paper Anti-PD-L1 checkpoint inhibitor combined with nanocarrier-mediated cisplatin codelivery system for effective treatment … DOI 10.1016/j.molimm.2024.08.006 ↗
- Paper Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic … DOI 10.1186/s12951-024-02646-7 ↗
Wei Wang · 1 shared paper, 2024 · strength 0.26
- Paper Anti-PD-L1 checkpoint inhibitor combined with nanocarrier-mediated cisplatin codelivery system for effective treatment … DOI 10.1016/j.molimm.2024.08.006 ↗
Hao Zhou · 1 shared paper, 2024 · strength 0.23
- Paper Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic … DOI 10.1186/s12951-024-02646-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.